Roche Obesity Drug Shows Strong Stay on Rate in Diabetes Patients

Roche’s obesity drug enicepatide shows strong stay-on rate in diabetes patients while delivering meaningful weight loss and blood-sugar control.

In a mid-stage trial, the once-weekly dual agonist helped overweight or obese people with type 2 diabetes lose an average of 15.5 percent of body weight.

Only about 2 percent of participants stopped treatment because of side effects. Weight loss had not yet plateaued.

These results position enicepatide as more than a single-agent contender. Roche already plans higher doses and combination studies that could turn the molecule into a backbone for next-generation multi-agonist or injectable plus oral regimens.

Strong Efficacy Meets High Treatment Persistence

Roche tested enicepatide, a once-weekly injection that mimics GLP-1 and GIP hormones, in 447 patients. The highest 24-milligram dose met both main goals of the study.

Key outcomes include:

• Average body-weight reduction of 15.5 percent at 48 weeks
• HbA1c decline of 2.65 percentage points
• About 62 percent of patients reaching HbA1c levels below 5.7 percent, moving blood sugar into the non-diabetic range
• Only 2 percent of patients discontinued because of side effects versus none on placebo
• Most gastrointestinal side effects remaining mild to moderate

Weight loss continued without plateau at the end of the 48 weeks. In an earlier mid-stage trial among overweight or obese patients without diabetes, the same drug produced 22.7 percent average weight loss.

Also Read: 10 GLP-1 Drugs Revolutionizing Diabetes & Obesity Treatment

Patient-Centric Advantage: Staying on Therapy Long Enough to Keep the Weight Off

A once-weekly dual agonist that keeps dropout rates low and weight loss ongoing at 48 weeks changes the practical equation for patients. High adherence supports sustained metabolic improvement and quality of life gains that paper percentages alone cannot deliver.

When only 2 percent of participants leave treatment because of side effects, far more people remain on therapy long enough for the 15.5 percent weight reduction to translate into durable benefit. This persistence profile stands out against higher discontinuation rates reported in shorter mid-stage trials of competing agents and strengthens the real-world case for enicepatide.

Next-Generation Combination Play: Enicepatide as the First Layer

Roche treats the current data as the first layer rather than the finished product. The company already runs two Phase 3 obesity studies and plans to start late-stage glycemic-control and cardiovascular-outcomes trials in the first half of 2027.

Teresa Graham, Roche’s pharmaceuticals chief, has stated that the organization explores both standalone and combination uses, especially for patients who seek greater weight reduction or tighter blood-sugar control.

Roche prepares to study higher doses of enicepatide and combinations with other weight-loss medicines. This strategy positions the dual agonist as a potential backbone for multi-agonist regimens or oral-plus-injectable pairings that could leapfrog existing market leaders.

What This Means for Patients with Type 2 Diabetes and Obesity

• Once-weekly dosing delivers 15.5 percent average weight loss and strong blood-sugar control at 48 weeks.
• Only 2 percent stop treatment due to side effects, supporting long-term adherence.
• Weight loss continues without plateau, aiding lasting results.
• Most side effects stay mild to moderate and manageable.
• Higher doses and combinations may offer greater future benefits.